Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.44 |
| ▸ | CA12 | O43570 | 3/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.33 |
| ▸ | RELA | Q04206 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.31 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24172307 | 0.88 | CA12 (0.39) | CA14CA12CA1CA7HDAC6 | |
| SCHEMBL21937996 | 0.86 | CA14 (0.41) | CA14CA12CA1CA7HDAC6 | |
| SCHEMBL8887438 | 0.84 | HDAC1 (0.40) | CA14CA12CA1CA7HDAC6 | |
| SCHEMBL23765988 | 0.83 | NR1I2 (0.36) | CA14CA12CA1CA7HDAC6 | |
| SCHEMBL7905771 | 0.83 | CA14 (0.44) | CA14CA12CA1CA7HDAC6 | |
| SCHEMBL3940725 | 0.82 | HDAC6 (0.39) | CA14CA12CA1CA7HDAC6 | |
| SCHEMBL929384 | 0.81 | HDAC6 (0.36) | CA14CA12CA1CA7HDAC6 | |
| SCHEMBL2608081 | 0.80 | CA14 (0.49) | CA14CA12CA1CA7HDAC6 | |
| SCHEMBL25074829 | 0.79 | HDAC6 (0.35) | CA14CA12CA1CA7HDAC6 | |
| SCHEMBL4061706 | 0.79 | TDP1 (0.42) | CA14CA12CA1CA7HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240197899-A1 | 2-AMINO-4-CARBOXAMIDE-BENZAZEPINE IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2024-06-20 | — | — | US | disclosed |
| EP-4313161-A1 | 2-AMINO-4-CARBOXAMIDE-BENZAZEPINE IMMUNOCONJUGATES, AND USES THEREOF | Bolt Biotherapeutics, Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| WO-2023102140-A1 | TMPRSS2 INHIBITORS AND METHODS OF USE | TOPSPIN THERAPEUTICS, INC. (US) | 2023-06-08 | — | — | WO | disclosed |
| US-20220195066-A1 | ANTI-CEA IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2022-06-23 | — | — | US | disclosed |
| WO-2022125904-A1 | ANTI-HER2 IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2022-06-16 | — | — | WO | disclosed |
| WO-2022125884-A1 | IMMUNOCONJUGATES COMPRISING AN ANTI-CEA ANTIBODY LINKED BY CONJUGATION TO ONE OR|MORE 8-HET-2- AMINOBENZAZEPINE DERIVATIVES USEFUL IN TREATING CANCER | BOLT BIOTHERAPEUTICS, INC. (US) | 2022-06-16 | — | — | WO | disclosed |
| WO-2022104079-A1 | PYRAZOLO[1,5-A]PYRAZINE DERIVATIVES AS BTK INHIBITORS | BIOGEN MA INC. (US) | 2022-05-19 | — | — | WO | disclosed |
| WO-2021239117-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | CULLGEN (SHANGHAI) , INC. (CN) | 2021-12-02 | — | — | WO | disclosed |
| EP-3526203-B1 | N-ARYL AND N-HETEROARYL PIPERIDINE DERIVATIVES AS LIVER X RECEPTOR BETA AGONISTS, COMPOSITIONS, AND THEIR USE | MERCK SHARP & DOHME (US) | 2021-09-22 | — | — | EP | disclosed |
| CN-109956957-A | A kind of big ring class kinase inhibitor of imidazo [1,2-b] pyridazine | 成都先导药物开发股份有限公司 | 2019-07-02 | — | — | CN | disclosed |
| US-20140057870-A1 | BICYCLIC TRIAZOLE AND PYRAZOLE LACTAMS AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | VANDERBILT UNIVERSITY (US) | 2014-02-27 | — | — | US | disclosed |
| WO-2013192347-A1 | SUBSTITUTED BICYCLIC CYCLOALKYL PYRAZOLE LACTAM ANALOGS AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | VANDERBILT UNIVERSITY (US) | 2013-12-27 | — | — | WO | disclosed |
| US-20130345204-A1 | SUBSTITUTED BICYCLIC CYCLOALKYL PYRAZOLE LACTAM ANALOGS AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | JANSSEN-CILAG, S.A. (ES) | 2013-12-26 | — | — | US | disclosed |
| US-8592422-B2 | Bicyclic triazole and pyrazole lactams as allosteric modulators of mGluR5 receptors | VANDERBILT UNIVERSITY (US) | 2013-11-26 | — | — | US | disclosed |
| EP-2651222-A1 | BICYCLIC TRIAZOLE AND PYRAZOLE LACTAMS AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | Vanderbilt University (US) | 2013-10-23 | — | — | EP | disclosed |
| EP-2648723-A1 | BICYCLIC PYRAZOLE COMPOUNDS AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | Vanderbilt University (US) | 2013-10-16 | — | — | EP | disclosed |
| US-20120295913-A1 | BICYCLIC PYRAZOLE COMPOUNDS AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | VANDERBILT UNIVERSITY | 2012-11-22 | — | — | US | disclosed |
| US-20120225844-A1 | BICYCLIC TRIAZOLE AND PYRAZOLE LACTAMS AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | JANSSEN-CILAG S.A. (ES) | 2012-09-06 | — | — | US | disclosed |
| WO-2012083224-A1 | BICYCLIC TRIAZOLE AND PYRAZOLE LACTAMS AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | VANDERBILT UNIVERSITY (US) | 2012-06-21 | — | — | WO | disclosed |
| WO-2012078817-A1 | BICYCLIC PYRAZOLE COMPOUNDS AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | VANDERBILT UNIVERSITY (US) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140057870-A1 | BICYCLIC TRIAZOLE AND PYRAZOLE LACTAMS AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | GRM5, GRIK5, GRIN3A | CA14 4774/4885CA12 4739/4885CA1 3387/4885 |
| US-20130345204-A1 | SUBSTITUTED BICYCLIC CYCLOALKYL PYRAZOLE LACTAM ANALOGS AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | GRM5, GRIK5, GRM3 | CA14 4692/4885CA12 4580/4885CA1 2945/4885 |
| US-20240197899-A1 | 2-AMINO-4-CARBOXAMIDE-BENZAZEPINE IMMUNOCONJUGATES, AND USES THEREOF | AADAC, BRD4, IDO2 | CA14 195/4885CA12 284/4885CA1 460/4885 |
| US-20220195066-A1 | ANTI-CEA IMMUNOCONJUGATES, AND USES THEREOF | EPHX2, FAAH2, CYP8B1 | CA14 21/4885CA12 15/4885CA1 217/4885 |
| US-20120225844-A1 | BICYCLIC TRIAZOLE AND PYRAZOLE LACTAMS AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | GRM5, GRIK5, GRIN3A | CA14 4774/4885CA12 4739/4885CA1 3387/4885 |
| US-20120295913-A1 | BICYCLIC PYRAZOLE COMPOUNDS AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | GRM5, GRIK5, GRM3 | CA14 4728/4885CA12 4605/4885CA1 2747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.